Curium Pharma
Tracked across 2 events · 12 articles · First seen Jun 11, 2026 · Last active Sep 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Curium Pharma, a global radiopharmaceutical company, is a key partner in the clinical development of 64Cu-PSMA-I&T and 177Lu-PSMA-I&T, leading global development and supporting technology transfer to Japan. The completion of patient dosing in the Phase 2 trial in Japan is a significant milestone for its mission to expand access to radiopharmaceuticals in Asia.
Jun 11, 2026 · 6 articles
Business
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, comprising $1.65 billion upfront plus up to $700 million in contingent milestone payments. The upfront…
Impact: Recently won FDA approval for Bexlutry and is closing its $8 billion purchase of Lantheus Holdings, making it a consolidating rival to the enlarged Telix.
Sep 21, 2026 · 6 articles
45
Curium Pharma acquiring Lantheus Lantheus HoldingsTelix acquires ITM Isotope...
40
United States — Food and Drug Administration approved Bexlutry Curium PharmaTelix acquires ITM Isotope...
ERGEN INTELLIGENCE
Track Curium Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard